FDA OKs New Option for Primary Biliary Cholangitis
MedPage Today) — The FDA granted accelerated approval to seladelpar (Livdelzi) for adults with primary biliary cholangitis (PBC), a rare and chronic autoimmune disease of the bile ducts, drugmaker Gilead Sciences announced on Wednesday. An oral…
MedPage Today) — The FDA granted accelerated approval to seladelpar (Livdelzi) for adults with primary biliary cholangitis (PBC), a rare and chronic autoimmune disease of the bile ducts, drugmaker Gilead Sciences announced on Wednesday.
An oral…
Read More
About Author
